Last reviewed · How we verify
Placebo oral vial
Placebo contains no active pharmaceutical ingredient and produces therapeutic effects primarily through the placebo effect—the patient's expectation of benefit.
Placebo oral vial, marketed by Federico II University, holds a unique position in the pharmaceutical market as a non-active substance used primarily in clinical trials. The key composition patent for Placebo oral vial is set to expire in 2028, which may provide a period of exclusivity and competitive advantage. However, the lack of a defined primary indication and revenue data poses a significant risk in assessing its market impact and potential competition.
At a glance
| Generic name | Placebo oral vial |
|---|---|
| Sponsor | Federico II University |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Placebo is an inert substance used as a control in clinical trials and sometimes therapeutically to leverage psychobiological mechanisms such as expectation, conditioning, and the mind-body interaction. It has no direct molecular or pharmacological action but can elicit measurable clinical responses in certain conditions, particularly those with subjective symptom components or high psychological influence.
Approved indications
- Clinical trial control arm (non-therapeutic use)
- Conditions responsive to placebo effect (e.g., pain, nausea, fatigue) in research settings
Common side effects
- Nocebo effect (adverse events attributed to placebo expectation)
Key clinical trials
- Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma (PHASE2)
- Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients (PHASE2)
- Study of LFD-200 in Healthy Adults and Adults With Moderate to Severe Rheumatoid Arthritis (PHASE1)
- A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial) (PHASE2)
- Optimal Timing of Ketamine Initiation for SCD Pain (PHASE3)
- Glucocorticoids Versus Placebo for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis (PHASE3)
- DBM-1152A Inhalation Solution in Healthy Volunteers (PHASE1)
- Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo oral vial CI brief — competitive landscape report
- Placebo oral vial updates RSS · CI watch RSS
- Federico II University portfolio CI